TET3 and acute myeloid leukemia: Mx1CreTet2fx/+Tet3fx/fx mice and Mx1CreTet2fx/fxTet3fx/+ mice developed AML at longer latencies, with a median survival of ∼27 weeks, suggesting a dose-dependent activity for Tet2 and Tet3 in AML development [20, 65].